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background:  For therapeutic monoclonal antibodies exhibiting nonlinear pharmacokinetic/dynamic properties, a doubling of dose may not 
result in a proportional change in efficacy or duration of effect. Evolocumab, a human monoclonal antibody against PCSK9, demonstrated 
significant and stable LDL-C reduction when dosed SC 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM). Lipid changes and safety 
data for these two regimens were compared to assess clinical equivalence.
Methods:  Data were analyzed from 3146 patients completing 1 of 4 12-week phase 3 studies. Percent reductions in LDL-C and other lipid 
parameters vs. control (placebo or ezetimibe) for patients receiving evolocumab 140 mg Q2W or 420 mg QM were reported as the average 
of week 10 and 12 values.
Results:  Mean (95% CI) percent changes in LDL-C from baseline were: -65.7 (-70.9, -60.6) and -65.0 (-69.5, -60.4) vs. placebo, and 
-38.9 (-41.3, -36.4) and -40.3 (-42.6, -38.0) vs. ezetimibe, for 140 mg Q2W and 420 mg QM dosing, respectively (Table). Changes in other 
lipid parameters were similar for both doses irrespective of background statin dose, race, gender, age, or cardiovascular risk. No notable 
imbalances in safety events were observed (Table).
conclusion:  Evolocumab 140 mg Q2W and 420 mg QM produces clinically equivalent changes in lipid parameters and are well tolerated. 
Higher doses extend the duration of LDL-C lowering such that a 3-fold higher dose of evolocumab dosed QM results in comparable 
changes in lipid parameters when compared to Q2W dosing.
Table. Lipid Changes and Safety by Evolocumab Dosing Regimen
Lipid Changes
Evolocumab 140 mg Q2W
(N=818)*
Evolocumab 420 mg QM
(N=825)*
Evolocumab 140 mg Q2W
(N=475)*
Evolocumab 420 mg QM
(N=475)*
vs Placebo vs Ezetimibe
Percent change from baseline at mean of weeks 10 and 12, %
LDL-C
Treatment difference vs control
(95% CI)
-65.7
(-70.9, -60.6)
-65.0
(-69.5, -60.5)
-38.9
(-41.3, -36.4)
-40.3
(-42.6, -38.0)
P value <0.001 <0.001 <0.001 <0.001
HDL-C
Treatment difference vs control
(95% CI)
6.4
(5.0, 7.8)
8.6
(7.0, 10.2)
6.4
(4.6, 8.3)
6.2
(3.9, 8.6)
P value <0.001 <0.001 <0.001 <0.001
TG
Treatment difference vs control
(95% CI)
-15.7
(-22.4, -8.9)
-21.1
(-24.9, -17.3)
-4.3
(-8.6, 0.0)
-8.0
(-13.2, -2.7)
P value <0.001 <0.001 0.052 0.003
ApoB
Treatment difference vs control
(95% CI)
-53.4
(-57.0, -49.7)
-54.3
(-56.4, -52.2)
-33.4
(-35.7, -31.1)
-36.6
(-39.3, -33.8)
P value <0.001 <0.001 <0.001 <0.001
Lp(a)
Treatment difference vs control
(95% CI)
-29.3
(-32.2, -25.4)
-27.7
(-30.6, -24.8)
-26.3
(-30.6, -22.0)
-27.9
(-35.2, -20.6)
P value <0.001 <0.001 <0.001 <0.001
Safety Data
n (%) Placebo(N=821)
Ezetimibe
(N=477)
Evolocumab
140 mg Q2W
(N=921)
Evolocumab
420 mg QM
(N=927)
Adverse events (AEs) 343 (41.8) 233 (48.8) 403 (43.8) 402 (43.4)
Serious AEs 19 (2.3) 7 (1.5) 24 (2.6) 16 (1.7)
Muscle-related AEs 24 (2.9) 37 (7.8) 32 (3.5) 35 (3.8)
Creatine kinase >5x ULN 6 (0.7) 3 (0.6) 1 (0.1) 4 (0.4)
ALT or AST >3x ULN 11 (1.3) 4 (0.8) 5 (0.5) 2 (0.2)
*372 subjects who received evolocumab 140 mg Q2W and 373 subjects who received evolocumab 420 mg QM were compared to both placebo (N=821) and ezetimibe control (N=477).
When the calculated LDL-C was <40 mg/dL or triglycerides were >400 mg/dL, calculated LDL-C was replaced with ultracentrifugation LDL-C from the same blood sample, if available.
Treatment difference is between evolocumab and control in percent change from baseline, estimated using Dersimonian-Laird random effect estimator.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein cholesterol; Lp(a), lipoprotein (a); Q2W, every 2 weeks; QM, monthly; TG, triglycerides
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